Durect
- Country
- Ownership
- -
- Employees
- 58
- Market Cap
- -
- Introduction
DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. Its pipeline is called DUR-928, an endogenous sulfated oxysterol and an epigenetic regulator. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.
Reply to 'An expert panel Consensus Statement on ALD without experts by experience'
K.W. is a member of the ACTIVE Workgroup supported by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, and Otsuka. J.L.M., B.P.L., and M.C.M. are consultants for GlaxoSmithKline, Novo Nordisk, HepaTX, and Prodigy. M.C.M. also serves on the Board of Amygdala Neuroscience and receives research support from Durect. Other authors declare no competing interests.
© Copyright 2024. All Rights Reserved by MedPath